
Macromoltek
Macromoltek is a YC Winter 2018 (W18) company. Based in Austin, TX, USA. Team of 14.
About Macromoltek
Summary
Macromoltek builds a computational platform that designs therapeutic antibodies for biotech and pharmaceutical companies. Using deep learning and structural modeling, it generates antibody candidates against targets that conventional wet-lab discovery methods cannot access, replacing experimental trial-and-error cycles with in silico design. Clients engage Macromoltek across early research through clinical development stages.
Business model
Flexible partnership models with biotech and pharma companies, scoped per project.
Go-to-market
Biotech and pharmaceutical companies are the buyers; they engage Macromoltek directly as a design and engineering partner, working through custom collaboration agreements rather than a self-serve product.
From the Y Combinator listing
Computational antibody design
Macromoltek: Revolutionizing antibody design. Description: Macromoltek, a computational de novo drug design company, rapidly produces accurate and credible antibody designs. We have built a proprietary platform that enables design against difficult targets inaccessible by traditional methods and have are already designing antibodies for large biopharmas and smaller biotechs.
Facts
- Healthcare / Healthcare -> Drug Discovery and Delivery
- Austin, TX, USA
- 14
- Active
- Early
Founders (2)
- Susana Kaufmann
Score every batch against your own thesis
GPAgent's sourcing agent reads every company in a batch, scores each one against your fund's thesis in a private workspace, and lines up the founders worth meeting before Demo Day. You decide who to contact. Your scores, notes, and pipeline never appear on these pages.
How Accelerator intelligence works